bluebird bio Inc (OQ:BLUE)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 60 Binney St
CAMBRIDGE MA 02142-1512
Tel: 1-410-9605022
Website: www.bluebirdbio.com
IR: See website
<
Key People
Daniel S. Lynch
Independent Chairman of the Board
Nick Leschly
President, Chief Executive Officer, Director
William D. Baird
Chief Financial Officer
Jason F. Cole
Chief Operating Officer and Legal Officer, Secretary
Kory James Wentworth
Principal Accounting Officer, Vice President - Finance, Treasurer
Philip D. Gregory
Chief Scientific Officer
David M. Davidson
Chief Medical Officer
Alison C. Finger
Chief Commercial Officer
Joanne M. Smith-Farrell
Chief Business Officer
Business Overview
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Financial Overview
For the six months ended 30 June 2020, bluebird bio Inc revenues increased from $25.8M to $220.8M. Net loss decreased 38% to $224.1M. Revenues reflect Collaborative arrangement revenue increase from $22.7M to $112M, Royalty revenue increase from $3M to $13.6M. Lower net loss reflects Stock-based Compensation in R&D decrease of 13% to $39.4M (expense), Change in fair value of contingent consi decrease from $510K (expense) to $4.8M (income).
Employees: 1,167 as of Jun 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $2,402M as of Jun 30, 2020
Annual revenue (TTM): $239.66M as of Jun 30, 2020
EBITDA (TTM): -$653.81M as of Jun 30, 2020
Net annual income (TTM): -$653.46M as of Jun 30, 2020
Free cash flow (TTM): -$492.54M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 66,222,965 as of Jul 31, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.